NAKAMURA Yusuke
No ORCID on file
· 160 papers in corpus
· active 2004-2011
Frequent coauthors
- KATAGIRI TOYOMASA 128
- OHSAWA RYUJI 32
- KONUMA AKIKO 16
- TSUNODA TAKUYA 16
- WATANABE TOMOHISA 16
- YOSHIMURA SACHIKO 16
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2011
Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…
2010
The invention features an isolated double-stranded molecule inhibiting a growth of GPC3 expressing cell. The invention also features a method for treating GPC3-related disease including esophageal cancer, gastric cancer, hepatic cancer, ost…